Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
2
Neutral
7
Bullish
5
Bearish
28
Neutral
7
Bullish
11
Bearish
26
Neutral
0
Bullish
6
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Shukra Pharmaceuticals Limited, founded in 1993, specializes in manufacturing and trading pharmaceutical formulations and conducting laboratory testing. Their offerings include a wide range of antibiotics, antifungal, antiviral, sedatives, and more.
The company operates four key manufacturing divisions: tablets, capsules, liquid, and small volume parental, situated in Gujarat.
It collaborates with major pharmaceutical manufacturers like Cadila Healthcare, Intas Pharmaceuticals, and others, aiding in the development of diverse drugs and formulations.
In 2013-14, Shukra Pharmaceuticals underwent a significant restructuring, including the amalgamation of Proper Dealcomm Private Limited and re-organization through a high court-approved scheme.
The company provides a broad spectrum of dosage forms to prestigious pharmaceutical companies worldwide, enhancing its market presence and industry reputation.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,277 Cr
Low Risk
57.9
34.1
0.4
14.2
65.26
12.97
Sales CAGR
Profit CAGR
ROE
ROCE
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is currently trading at 30.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Shukra Pharmaceuticals Limited, founded in 1993, specializes in manufacturing and trading pharmaceutical formulations and conducting laboratory testing. Their offerings include a wide range of antibiotics, antifungal, antiviral, sedatives, and more. The company operates four key manufacturing divisions: tablets, capsules, liquid, and small volume parental, situated in Gujarat. It collaborates with major pharmaceutical manufacturers like Cadila Healthcare, Intas Pharmaceuticals, and others, aiding in the development of diverse drugs and formulations. In 2013-14, Shukra Pharmaceuticals underwent a significant restructuring, including the amalgamation of Proper Dealcomm Private Limited and re-organization through a high court-approved scheme. The company provides a broad spectrum of dosage forms to prestigious pharmaceutical companies worldwide, enhancing its market presence and industry reputation.
Over the past 52 weeks, Shukra Pharmaceuticals Ltd has traded between a low of ₹12.97 and a high of ₹65.26. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Shukra Pharmaceuticals Ltd has a market capitalization of approximately 1,276.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Shukra Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 57.91 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,276.86 Cr, Shukra Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Shukra Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Shukra Pharmaceuticals Ltd is 57.91. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' scheme, a ₹10,000 crore initiative aimed at making India a global biopharmaceutical manufacturing hub, which will improve the entire industry ecosystem.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
208.80 | 1,379 Cr | 32.02 | 5.00 | 1.94 | 15.60 | 20.59 | 13.60 | ||
158.15 | 1,377 Cr | 33.25 | 0.99 | 0.00 | 3.57 | 4.36 | 2.47 | ||
13.88 | 1,305 Cr | 17.07 | 3.14 | 0.00 | 18.42 | 24.46 | 14.32 | ||
29.16 | 1,277 Cr | 57.91 | 14.21 | 0.03 | 24.55 | 31.50 | 18.78 | ||
630.00 | 1,261 Cr | 14.34 | 1.66 | 0.29 | 11.60 | 15.18 | 9.87 | ||
2249.55 | 1,240 Cr | 33.10 | 4.38 | 0.03 | 11.73 | 15.97 | 5.83 | ||
449.90 | 1,079 Cr | 24.61 | 3.92 | 0.22 | 15.92 | 21.28 | 13.63 | ||
| Median: 7 Co. | — | 208.80 | 1,277 Cr | 32.02 | 3.92 | 0.03 | 15.60 | 20.59 | 13.60 |
Preferential Warrant Issue
Shukra Pharmaceuticals will hold an EGM on 06-Jul-2026 to seek shareholder approval under SEBI ICDR Reg 170(2) for a preferential issue of 4,643,000 convertible equity warrants to promoters at Rs.35.56 each (total ~Rs.16.51 Cr).
Preferential Warrant Issue
Shukra Pharmaceuticals to hold EGM on 06-Jul-2026 to seek shareholder approval under SEBI ICDR Reg 170(2) for preferential issue of 46,43,000 convertible equity warrants to promoters at Rs.35.56 each (aggregate Rs.16.51 Cr).
Preferential Issue
Board approved seeking fresh shareholder approval by special resolution for preferential issue of 4,643,000 convertible equity warrants (1 share per warrant); issue price to be recomputed per SEBI ICDR (floor Rs.34), EGM on Jul 06, 2026; scrutinizer appointed.
